SEC Tracker
Get the app

Dianthus Therapeutics DNTH

Dianthus Therapeutics Q2 FY25: revenue $193K, down 90%; diluted EPS −$0.88

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Dianthus Therapeutics reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$193K−90% from $1.9M in Q2 FY2410-Q income statement, on EDGAR
  2. Net income−$31.6MAgainst −$17.6M in Q2 FY2410-Q income statement, on EDGAR
  3. Diluted EPS−$0.88Against −$0.51 in Q2 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$13.2M−96% from $314.2M in Q2 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$23.9MAgainst −$14.5M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Dianthus Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Stoke Therapeutics STOK public float $592M, Jun 30, 2025
  2. Trevi Therapeutics TRVI public float $588M, Jun 30, 2025
  3. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025
  4. Anaptysbio ANAB public float $633M, Dec 31, 2025
  5. Evolus EOLS public float $560M, Jun 30, 2025